Showing 501 - 520 results of 27,650 for search '(( 50 ((teer decrease) OR (a decrease)) ) OR ( 50 ((mean decrease) OR (we decrease)) ))', query time: 1.08s Refine Results
  1. 501
  2. 502
  3. 503

    Cellular proliferation is decreased in LV-shRNA-ADAMTS-1 transduced vessels. by Evelyn C. Nieves Torres (551495)

    Published 2014
    “…By day 7, there is a significant decrease in the mean Ki-67 index in the <b>LV</b> transduced vessels when compared to <b>C</b> at day 7 (P<0.01). …”
  4. 504

    Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

    Published 2016
    “…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
  5. 505
  6. 506
  7. 507
  8. 508
  9. 509
  10. 510

    Increased lipid accumulation and decreased klotho expressions in palmitate-treated mouse podocytes. by Jeong Suk Kang (7359572)

    Published 2021
    “…Boxes are enlarged images of representative lipid droplets. magnification 20x; scale bar = 50 μm and 100 μm. (c) Western blot showing the decreased expression of klotho and nephrin proteins by palmitate treatment. …”
  11. 511
  12. 512
  13. 513
  14. 514
  15. 515
  16. 516
  17. 517

    WNT3 decreases GCP proliferation by inhibiting SHH dependent gene transcription. by Sandrine L. Anne (489755)

    Published 2013
    “…<p>(<i>A</i>) WNT3 decreased proliferation of GCPs by 40.3± 5.0% of the control (Con) (n=3) as measured by [<sup>3</sup>H]-Thymidine incorporation assay. …”
  18. 518
  19. 519
  20. 520

    Decreased Risk of Ventilator-Associated Pneumonia in Sepsis Due to Intra-Abdominal Infection by François Philippart (319324)

    Published 2015
    “…The IAI group had fewer patients with VAP (56 [19.3%] <i>vs</i>. 806 [34.5%], <i>P</i><0.01) and longer time to VAP (5.0 <i>vs</i>.10.5 days; <i>P</i><0.01). After adjustment on independent risk factors for VAP and previous antimicrobial use, IAI was associated with a decreased risk of VAP (hazard ratio, 0.62; 95% confidence interval, 0.46–0.83; <i>P</i><0.0017). …”